Pharmaceuticals
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.
This page shows you the most recent publications within this specialty of the MedWorm directory. This is page number 6.
bioMerieux and GSK Sign Theranostics Agreement to Develop Predictive Test for Selecting Breast Cancer Treatment
Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
MARCY L'ETOILE, France, Nov. 17 (HSMN NewsFeed) -- bioMerieux has signed an agreement with GlaxoSmithKline to develop a predictive test to help clinicians select the most appropriate treatment for different segments of breast cancer patients. This test, ... Biopharmaceuticals, Diagnostics, OncologybioMerieux, GlaxoSmithKline, Theranostics, personalized medicine, breast cancer
Source: HSMN NewsFeed - November 17, 2009 Category: Pharmaceuticals Source Type: news
Pioneer(R) Surgical Technology, Inc. and Bonovo(R) Orthopedics, Inc. Establish Foothold in Fastest Growing Spine Market in the WorldEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Companies launch major product introduction for the 2009 Chinese Orthopaedic Association meeting in Xiamen.
MARQUETTE, Mich., Nov. 17 (HSMN NewsFeed) -- Bonovo Orthopedics, Inc., a leading Chinese manufacturer and distributor of orthopedic products, h... Devices, Orthopaedic, Neurosurgery, Regulatory, DistributionPioneer Surgical Technology, Bonovo Orthopedics
Source: HSMN NewsFeed - November 17, 2009 Category: Pharmaceuticals Source Type: news
IDEV Technologies Names Christopher M. Owens President, Chief Executive OfficerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
William W. Burke Appointed Executive Vice President, Chief Financial Officer
HOUSTON, Nov. 17 (HSMN NewsFeed) -- IDEV Technologies, Incorporated (IDEV), an emerging leader in the development and marketing of minimally invasive medical technologies, to... Devices, Interventional, PersonnelIDEV Technologies
Source: HSMN NewsFeed - November 17, 2009 Category: Pharmaceuticals Source Type: news
Ellipse Technologies, Inc. Receives CE Mark Clearance for the MAGEC(TM) System for the treatment of Spinal ScoliosisEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
MAGEC System Provides Non-Invasive Remote Control Spine Therapy
IRVINE, Calif.--(HSMN NewsFeed)--Ellipse Technologies, Inc. (Ellipse) announced today it has received CE Mark (Conformité Européenne) for its MAGEC(TM) Technology for the tr... Devices, Orthopaedic, Neurosurgery, RegulatoryEllipse Technologies, MAGnetic Expansion Control, scoliosis
Source: HSMN NewsFeed - November 17, 2009 Category: Pharmaceuticals Source Type: news
YM Biosciences Reports Cyt997 Oral Vascular Disrupting Agent Results Presented At AACR-NCI-EORTC MeetingEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
MISSISSAUGA, ON, November 17, 2009 /PRNewswire-FirstCall/ - YM
BioSciences Inc. , a life sciences product development company that
identifies and advances a diverse portfolio of promising
cancer-related products at various stages of development,...
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials
American Heart Association Late Breaking Clinical Trial Report: High Dose of Angiotensin Receptor Blockers Effective in Heart Failure PatientsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Study highlights: -- Iron treatment with intravenous (I.V.)
ferric carboxymaltose significantly improved symptoms, functional
capacity and quality of life for Class II and III chronic heart
failure (CHF) patients. -- This treatment worked equally...
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials
Semafore Pharmaceuticals Announces Phase I Data Presentation Highlighting Novel PI3K Pathway Inhibitor at 51st ASH Annual MeetingEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
INDIANAPOLIS--(BUSINESS WIRE)--Nov 16, 2009 - Researchers are
scheduled to present Phase I data relating to Semafore
Pharmaceuticals' lead product candidate, SF1126, as a treatment for
patients with relapsed and refractory myeloma during the...
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials
BioSante Pharmaceuticals Comments on Boehringer Ingelheim Clinical Test Results in Treatment of Female Sexual DysfunctionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nov 16, 2009 - BioSante
Pharmaceuticals, Inc. (NASDAQ: BPAX), a specialty pharmaceutical
company developing products for female sexual health, including
LibiGel® for the treatment of hypoactive sexual
desire...
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials
Aegerion Pharmaceuticals Announces Additional Lomitapide (AEGR-733) Phase III Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Safety ProfileEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Results Will Be Presented Today At AHA Conference in Orlando,
Florida
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Nov 16, 2009 - Aegerion
Pharmaceuticals, Inc., a biopharmaceutical company focused on the
treatment of cardiovascular and metabolic...
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials
Pluristem Therapeutics Announces Three Month Follow-Up Data from the First Patient to Receive PLX-PADEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Data Suggests PLX-PAD is Safe, with Noted Improvement in
Measured Efficacy Parameters
HAIFA, Israel--(BUSINESS WIRE)--Nov 17, 2009 -
Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT) today
announced that safety and potential efficacy...
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials
Higher Dose of Merck's Cozaar (losartan potassium tablets) Significantly Reduced Deaths and Hospitalizations Due to Heart Failure In Investigational StudyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Results from HEAAL Study Presented as Late-Breaker at American
Heart Association Scientific Sessions 2009
ORLANDO, Fla.--(BUSINESS WIRE)--Nov 17, 2009 - In an
investigational study, Merck's medicine COZAAR (losartan potassium
tablets) 150 mg,...
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials
NeoPharm Presents the Phase I Data for Patients with Metastatic Solid TumorsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
LAKE BLUFF, Ill.--(BUSINESS WIRE)--Nov 17, 2009 - NeoPharm, Inc.
(Other OTC: NEOL.PK) today announced the results of a Phase I
clinical trial of Liposome Encapsulated Docetaxel (LE-DT) an active
component of Taxotere® at a joint International...
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials
Merck's Investigational Anacetrapib Phase IIb Study Results Presented at American Heart Association Annual Scientific SessionsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Persistent Lipid Effects Remained in the Higher Dose Arms
After Cessation Of Therapy in Patients with Dyslipidemia
ORLANDO, Fla.--(BUSINESS WIRE)--Nov 17, 2009 - In a phase IIb
study in 589 patients with primary hypercholesterolemia or...
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials
Interim Phase 2 Survival Data for PV-10 Will Be Presented by Professor John F. Thompson, MD, on November 21, 2009Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Lead Investigator for Provectus' PV-10 Trial Will Present At
3rd World Meeting of Interdisciplinary
Melanoma/Skin Cancer Centers in Berlin
Will Update Compassionate Use Program
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Nov 17, 2009 -...
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials
Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor XL147 (SAR245408) in Combination with Paclitaxel and Carboplatin at the AACR-NCI-EORTC ConferenceEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
BOSTON--(BUSINESS WIRE)--Nov 17, 2009 - Exelixis, Inc.
(Nasdaq:EXEL) today reported interim data from an ongoing phase 1
dose-escalation trial of XL147 (SAR245408) in combination with
paclitaxel and carboplatin in patients with advanced solid...
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials
ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell CarcinomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
WALTHAM, Mass.--(BUSINESS WIRE)--Nov 17, 2009 -
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company
that develops targeted anticancer therapeutics, today reported
encouraging clinical data with its IMGN901 product candidate in the
treatment...
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials
AVEO's Triple VEGF Receptor Inhibitor Tivozanib in Combination with mTOR Inhibitor Demonstrates Anti-tumor Activity and Tolerability in Advanced Kidney Cancer; Preliminary Results Presented at AACR-NCI-EORTC MeetingEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Preclinical Combination Data Also Presented, Demonstrate
mTOR-Tivozanib Combination in Breast Tumor Model Prevents Emergence
of Resistance
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 17, 2009 - AVEO
Pharmaceuticals, Inc., a biopharmaceutical company...
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials
Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial ResultsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
- Data Presented at AACR-NCI-EORTC's "Molecular Targets and
Cancer Therapeutics" International Conference -
SOUTH SAN FRANCISCO, Calif., Nov. 17 /PRNewswire-FirstCall/ --
Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) today announced updated...
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials
ICU Medical, Inc. Expands Its Relationship With MedAssets Supply Chain Systems by Signing Two New Contracts for Critical Care Products Including a Next Generation SELECT AgreementEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SAN CLEMENTE, Calif., Nov. 17, 2009 (GLOBE NEWSWIRE) -- ICU Medical, Inc., (Nasdaq:ICUI), a leading low cost manufacturer of safe medical connectors, custom medical products and critical care devices, today announced that it has entered into contracts for Invasive Hemodynamic monitoring products with MedAssets Supply Chain Systems. MedAssets Supply Chain Systems is one of the nation's largest group purchasing organizations (GPO), providing innovative solutions for healthcare providers to improve their margins and cash flow. These contracts offer MedAssets' customers ICU Medical's leading line of Disposable Transducers, The...
Source: Medical News (via PRIMEZONE) - November 17, 2009 Category: Pharmaceuticals Source Type: news
Freelancers Vs. ObamaCareEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
One-size-fits-all insurance reform could stamp out innovation that's already providing coverage and controlling costs.
Source: Forbes.com Healthcare News - November 17, 2009 Category: Pharmaceuticals Source Type: news
OXiGENE Reports Positive Safety Data From Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer at the 2009 AACR-NCI-EORTC ConferenceEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today reported positive interim safety data from the FALCON (Fosbretabulin in Advanced Lung Oncology) study, a Phase 2, randomized, controlled study of ZYBRESTAT (fosbretabulin) in patients with advanced non-small cell lung cancer (NSCLC). The data from this planned interim safety analysis indicated that the combination of fosbretabulin with carboplatin and paclitaxel plus bevacizumab (Avastin(R)) appeared to ...
Source: Medical News (via PRIMEZONE) - November 17, 2009 Category: Pharmaceuticals Source Type: news
Scientific Industries Reports Results for QuarterEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
BOHEMIA, N.Y., Nov. 17, 2009 (GLOBE NEWSWIRE) -- Scientific Industries Inc. (OTCBB:SCND) reported yesterday improved operating results for the first quarter of the current fiscal year compared with the first quarter of the prior fiscal year -- Net income of $43,500 ($.04 per basic share) for the three months ended September 30, 2009 vs. a net loss of ($78,100) ($.07 per basic share) for the three months ended September 30, 2008. The improvement was mainly the result of an increase of $271,700 (28%) in net sales to $1,244,000.
Source: Medical News (via PRIMEZONE) - November 17, 2009 Category: Pharmaceuticals Source Type: news
FDA and Everyday Health Collaborate to Expand Reach of Consumer Health InformationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
WASHINGTON & BROOKLYN, N.Y.--(BUSINESS WIRE)--Nov 17, 2009 -
The U.S. Food and Drug Administration (FDA) and
Everyday Health today announced a collaboration that will
expand the delivery of the agency's vital consumer health
information to the...
Source: Drugs.com - Pharma News - November 17, 2009 Category: Pharmaceuticals Source Type: news
Common Cold Virus May Have Foiled HIV Vaccine TestEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Associated Press - Nov. 16, 2009
WASHINGTON-The failure of an experimental AIDS vaccine trial two
years ago may have been caused by the common cold virus.
The vaccine was intended to block the spread of HIV, which
causes AIDS. But the test was...
Source: Drugs.com - Pharma News - November 17, 2009 Category: Pharmaceuticals Source Type: news
Duke University Initiates Study of AEOL 10150 to Measure Compound's Ability to Protect Healthy Tissue in Mice Receiving Chemotherapy and Radiation for Non-Small Cell Lung CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
MISSION VIEJO, Calif.--(HSMN NewsFeed)--Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS ) announced today the initiation of a study to test the anti-tumor effects of AEOL 10150 when combined with radiation and chemotherapy in nude mice bearing human... Biopharmaceuticals, OncologyAeolus Pharmaceuticals, AEOL 10150, radiotherapy, non-small cell lung cancer
Source: HSMN NewsFeed - November 17, 2009 Category: Pharmaceuticals Source Type: news
Abbott to Develop New Heart Failure Test on ARCHITECT(R) Immunochemistry Diagnostics PlatformEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
ABBOTT PARK, Ill. and WALTHAM, Mass., Nov. 17 (HSMN NewsFeed) -- Abbott (NYSE: ABT ) and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development a... Diagnostics, CardiologyAbbott, BG Medicine, immunochemistry, galectin-3, heart failure
Source: HSMN NewsFeed - November 17, 2009 Category: Pharmaceuticals Source Type: news
Lonza Receives Technology Leadership of the Year Award from Frost and SullivanEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: PharmaManufacturing.com - November 17, 2009 Category: Pharmaceuticals Authors: Pharma Manufacturing Source Type: info
Market Intelligence Report: Tracking Your WorkforceEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
While many drug manufacturers are successfully tracking their workers in terms of attendance, skills, training, and habits, our recent survey shows there is much room for improvement. Most notably, there are still many manufacturers who are tracking workers on paper, or are not getting critical information that could be beneficial. This video-the first of a series of reports by PharmaManufacturing.com-provides an overview of our survey data and suggests how manufacturers can leverage workforce knowledge for operational improvement. A PDF of our final survey data is also available.
Source: PharmaManufacturing.com - November 17, 2009 Category: Pharmaceuticals Authors: Pharma Manufacturing Source Type: info
Drug Therapy More Cost-Effective Than Angioplasty for Diabetic Patients with Heart Disease, Stanford Researcher FindsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
STANFORD, Calif.--(BUSINESS WIRE)--Nov 17, 2009 - Many patients
with diabetes should forego angioplasties for heart disease and
just take medicine instead, according to a new National Institutes
of Health study led by Stanford University School of...
Source: Drugs.com - Pharma News - November 17, 2009 Category: Pharmaceuticals Source Type: news
Genzyme Flops at FDA: Allston Plant Problems Delay Drug Review [Boston Herald]Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Boston Herald (MA) - Nov. 17, 2009
Nov. 17--The U.S. Food and Drug Administration is holding off on
its review of Lumizyme, a treatment
for the rare muscular disorder Pompe disease, until drug maker
Genzyme Corp. resolves manufacturing
problems at...
Source: Drugs.com - Pharma News - November 17, 2009 Category: Pharmaceuticals Source Type: news
FDA Reviews Update to Pfizer Vaccine for KidsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Associated Press - Nov. 16, 2009
WASHINGTON-Federal health officials on Monday questioned whether
to approve an updated version of Pfizer
's best-selling anti-infection vaccine for children,
despite company studies that failed to meet certain...
Source: Drugs.com - Pharma News - November 17, 2009 Category: Pharmaceuticals Source Type: news
Novartis: Lower Dose of Flu Vaccine SufficientEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Associated Press - Nov. 17, 2009
BASEL, Switzerland–Pharmaceutical maker
Novartis AG said Tuesday a U.S.
clinical study suggests that half a dose of its swine flu vaccine
may be sufficient to protect people from the virus and could...
Source: Drugs.com - Pharma News - November 17, 2009 Category: Pharmaceuticals Source Type: news
FDA Says Prilosec Can Block Benefits of PlavixEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
From Associated Press (November 17, 2009)
WASHINGTON–Federal health officials say a popular
heartburn medication can block the blood thinning effect of Plavix,
which is taken by millions of Americans to reduce risks of heart
attack and...
Source: Drugs.com - Pharma News - November 17, 2009 Category: Pharmaceuticals Source Type: news
Health Sciences Quest - Medical MarijuanaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
INDIAN HARBOUR BEACH, Fla., Nov. 17, 2009 (GLOBE NEWSWIRE) -- Health Sciences Group, Inc. (Pink Sheets:HESG) would like to announce that it has retained its attorney Robert Young to investigate the necessary steps to legally obtain licensing care giving and growing of Medical Marijuana in the State of California. One of which is forming a non-profit organization.
Source: Medical News (via PRIMEZONE) - November 17, 2009 Category: Pharmaceuticals Source Type: news
American Heart Association Late Breaking Clinical Trial Report: Treatment for Iron Deficiency Improves Symptoms, Functional Capacity and Quality of Life in Chronic Heart Failure PatientsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Study highlights: -- Iron treatment with intravenous (I.V.)
ferric carboxymaltose significantly improved symptoms, functional
capacity and quality of life for Class II and III chronic heart
failure (CHF) patients. -- This treatment worked equally...
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials
Neptune Technologies & Bioressources Inc. Reports on Medical Food Candidate Preclinical Research; Pilot ADHD Effect is ConfirmedEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
LAVAL, Quebec, Nov. 17, 2009 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX-V:NTB) announced today the first preclinical research up-date on NeuroBioPharm Inc. ("NBP") medical food development program.
Source: Medical News (via PRIMEZONE) - November 17, 2009 Category: Pharmaceuticals Source Type: news
Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC MeetingEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CALGARY, Nov. 17 /PRNewswire-FirstCall/ -- Oncolytics Biotech
Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today
announced updated results from a Phase I/II U.K. trial (REO 011) of
REOLYSIN(R) combined with paclitaxel/carboplatin for...
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials
Device Improves Heart-Failure SurvivalEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
A new heart-pumping device worked significantly better in heart-failure patients who were ineligible for a heart transplant than an older, approved device.
Source: WSJ.com: Health - November 17, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
Data from Mipomersen Phase 3 Trial in hoFH Patients Presented at AHAEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Study Meets Primary Endpoint with
25 Percent LDL Reduction in Very High-Risk Patient
Population
CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Nov.
17, 2009--
Genzyme Corp. (NASDAQ: GENZ) and
Isis Pharmaceuticals Inc. (NASDAQ:...
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials
Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV (guanfacine) Extended-Release Tablets with StimulantsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
...
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials
New Heart Pump Extends LivesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Device offers hope to the sickest heart failure patients.
Source: Forbes.com Healthcare News - November 17, 2009 Category: Pharmaceuticals Source Type: news
The Medicines Company Announces Positive Phase III Data in Two Late-Breakers at AHA and in NEJMEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Data from Two International Trials with nearly 14,000 Patients
Presented at American Heart Association Scientific Sessions and
Published in Two Papers in the New England Journal of Medicine
Parsippany, N.J., November 15, 2009—The Medicines...
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials
Ticagrelor (BRILINTAT) Demonstrated Greater Efficacy Over Clopidogrel in the Most Urgent Clinical SettingEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Orlando, FL -November 15, 2009 – AstraZeneca (NYSE:
AZN) today announced results of a PLATO sub-analysis in the most
serious type of Acute Coronary Syndrome (ACS) patients, those with
ST Segment Elevation Myocardial Infarction (STEMI)....
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials
Allon Therapeutics Inc.: Allon Chosen as "Top 10 Partnering Candidate" and Presenting at Major Partnership ConferenceEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
VANCOUVER, BRITISH COLUMBIA (MARKET WIRE) Allon Therapeutics Inc. (TSX: NPC) announced today its lead drug candidate, davunetide, has been selected as one of the Top 10 partnership candidates by a leading industry expert. The 2009 Windhover Therapeutic Areas Partnership Conference features the Top 10 candidates. Bruce Morimoto, Vice-President of Drug Development at Allon, will present an overview of the davunetide program at the conference in Boston, MA on November 18.
Source: Market Wire - Pharmaceuticals and Biotech - November 17, 2009 Category: Pharmaceuticals Tags: Pharmaceuticals and Biotech NPC Source Type: news
XOMA Appoints Jim Neal Vice President of Business DevelopmentEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
BERKELEY, Calif., Nov. 17--(HSMN NewsFeed) -- XOMA Ltd. (Nasdaq:XOMA ), a leader in the discovery and development of therapeutic antibodies, today announced that James R. Neal has joined the company as Vice President, Business Development. Mr. Neal will ov... Biopharmaceuticals, PersonnelXOMA
Source: HSMN NewsFeed - November 17, 2009 Category: Pharmaceuticals Source Type: news
CDC chief: Employers play big role in health careEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Employers play a key role in attacking the national problems of heart disease and stroke, the director of the U.S. Centers for Disease Control and Prevention said during a visit to Kansas City.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 17, 2009 Category: Pharmaceuticals Source Type: journals
CONMED Linvatec Announces Launch of Novel Biocomposite Technology and Related Matryx(TM) Biocomposite Interference ScrewsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
UTICA, NY, Nov 17--(HSMN NewsFeed) - CONMED Corporation's (NASDAQ:CNMD ) CONMED Linvatec arthroscopy unit today announced the release of new sizes of its Matryx(TM) Biocomposite Interference Screw. These new screws represent the latest advance in biocompos... Devices, OrthopaedicCONMED, CONMED Linvatec, Matryx, Interference Screw
Source: HSMN NewsFeed - November 17, 2009 Category: Pharmaceuticals Source Type: news
Entellus Medical® Secures $30 Million Financing To Expand Commercialization of Novel Treatments for SinusitisEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
New treatment offers less invasive approach in $1 billion world-wide chronic sinusitis market
MINNEAPOLIS, Nov 17--(HSMN NewsFeed)--Entellus Medical, the Minnesota-based developer of novel, less invasive treatments for chronic conditions of sinusitis, h... Devices, Venture CapitalEntellus Medical
Source: HSMN NewsFeed - November 17, 2009 Category: Pharmaceuticals Source Type: news
Entellus Medical(R) Secures $30 Million Financing To Expand Commercialization of Novel Treatments for SinusitisEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
New treatment offers less invasive approach in $1 billion world-wide chronic sinusitis market
MINNEAPOLIS, Nov 17--(HSMN NewsFeed)--Entellus Medical, the Minnesota-based developer of novel, less invasive treatments for chronic conditions of sinusitis, h... Devices, Venture CapitalEntellus Medical
Source: HSMN NewsFeed - November 17, 2009 Category: Pharmaceuticals Source Type: news
DeCODE genetics Files for BankruptcyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
DeCODE genetics filed for bankruptcy protection, effectively putting an end to the Icelandic genetics-research company's 13-year history with it never having turned a profit.
Source: WSJ.com: Health - November 17, 2009 Category: Pharmaceuticals Tags: PAID Source Type: news
